Page last updated: 2024-11-13
laidlomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
laidlomycin: polycyclic, polyether, monocarboxylic acid posessing inhibitory activity against various Mycoplasma species, especially Acholeplasma laidlawii; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71454116 |
| CHEMBL ID | 2205250 |
| MeSH ID | M0055540 |
Synonyms (28)
| Synonym |
|---|
| 16-deethyl-3-o-demethyl-16-methyl-3-o-(1-oxopropyl)monensin |
| brn 1675244 |
| laidlomycin |
| laidlomycin [inn:ban] |
| laidlomicina [inn-spanish] |
| einecs 260-095-1 |
| laidlomycine [inn-french] |
| monensin, 16-deethyl-3-o-demethyl-16-methyl-3-o-(1-oxopropyl)- |
| laidlomycinum [inn-latin] |
| 56283-74-0 |
| CHEMBL2205250 |
| unii-mi3s6zf5qe |
| mi3s6zf5qe , |
| laidlomycine |
| laidlomicina |
| laidlomycinum |
| laidlomycin [inn] |
| laidlomycin [mi] |
| ZNBNBTIDJSKEAM-NISBWGIBSA-N |
| Q15725701 |
| (2s,3r,4r)-4-[(2s,5r,7s,8r,9s)-7-hydroxy-2-[(2r,5s)-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic a |
| DTXSID401024015 |
| laidlomicina (inn-spanish) |
| laidlomycinum (inn-latin) |
| csu-1 |
| 16-deethyl-3-o-demethyl-16-methyl-3-o-(1-oxopropyl) monensin |
| laidlomycine (inn-french) |
| AKOS040746980 |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The objective of this research was to use data from multiple studies to comprehensively quantify the effects of feeding 1) laidlomycin propionate (LP), alone and/or in combination with chlortetracycline, compared with 2) monensin sodium (MS), alone and/or in combination with tylosin, at commercially approved dosages, on ADG, DMI, feed efficiency (FE), mortality, and carcass characteristics (HCW and liver abscesses)." | ( Meta-analysis of the effects of laidlomycin propionate, fed alone or in combination with chlortetracycline, compared with monensin sodium, fed alone or in combination with tylosin, on growth performance, health, and carcass outcomes in finishing steers in Branine, M; Cernicchiaro, N; Corbin, M; Prouty, F; Quinn, M; Renter, DG, 2016) | 0.92 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "75% BW) or steers were dosed intraruminally with a 100% concentrate diet." | ( Efficacy of laidlomycin propionate to reduce ruminal acidosis in cattle. Bauer, ML; Britton, RA; Herold, DW; Klopfenstein, TJ; Stock, RA; Yates, DA, 1995) | 0.67 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID716395 | Potentiation of colchicine-induced cytotoxicity in human KB-C4 cells at 1 ug/mL relative to control | 2012 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23 | Polyether ionophores-promising bioactive molecules for cancer therapy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (27)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (22.22) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 24.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (6.90%) | 5.53% |
| Reviews | 2 (6.90%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 25 (86.21%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||